Contact us : info@bioworlde.com
Home > Product > Primary Antibodies
COVID-19 S-hIgG1 Human monoclonal neutralizing antibody MB66243
  • Immobilized Recombinant COVID-19 S Protein RBD-SD1 at 5 ug/ml can bind Anti-COVID-19 S-hIgG1 Neutralizing Antibody, the EC50 is less than 4.8 ng/ml.
  • Anti-COVID-19 S-hIgG1 Neutralizing Antibody can block Recombinant Human ACE2 Protein and Recombinant COVID-19 S Protein RBD-SD1 interaction, the IC50 for this effect is 165 ng/ml.
Product NameCOVID-19 S-hIgG1 Human monoclonal neutralizing antibody
Catalog No.MB66243
Swiss-ProtP0DTC2
Host Human Cells
ReactivityCOVID-19
ApplicationsELISA
Application_allELISA: Use at an assay dependent dilution.
BiowMW
Alternative NameSpike glycoprotein; S glycoprotein; E2; Peplomer protein
Purification&Purity>95%, cultured in vitro under conditions free from animal derived components.
ConjugateUnconjugated
ModificationUnmodification
Browse similar products>>
Size Price
50ul $158
100ul $275
Add to cart My orders
Product Name :
COVID-19 S-hIgG1 Human monoclonal neutralizing antibody
Background :
The cause of the COVID-19 pandemic is a novel and highly pathogenic coronavirus, termed SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 is a member of the Coronaviridae family of viruses. The genome of SARS-CoV-2 is similar to other coronaviruses, and is comprised of four key structural proteins: S, the spike protein, E, the envelope protein, M, the membrane protein, and N, the nucleocapsid protein. Coronavirus spike proteins are class I fusion proteins and harbor an ectodomain, a transmembrane domain, and an intracellular tail. The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases at S1/S2 and S2’ sites. S1 and S2 subunits remain associated after cleavage and assemble into crown-like homotrimers. In humans, both SARS-CoV and SARS-CoV-2 spike proteins utilize the angiotensin-converting enzyme 2 (ACE2) protein as a receptor for cellular entry. Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors.
Product :
1 mg/ml. Human IgG1. Liquid in 0.01M Phosphate Buffered Saline, pH 7.4.
Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :
Recognizes COVID-19 S Protein, COVID-19 S-RBD Protein and block ACE-2 receptor binding.
Immunogen :
Conjugate :
Unconjugated
Modification :
Unmodification
  • Immobilized Recombinant COVID-19 S Protein RBD-SD1 at 5 ug/ml can bind Anti-COVID-19 S-hIgG1 Neutralizing Antibody, the EC50 is less than 4.8 ng/ml.
  • Anti-COVID-19 S-hIgG1 Neutralizing Antibody can block Recombinant Human ACE2 Protein and Recombinant COVID-19 S Protein RBD-SD1 interaction, the IC50 for this effect is 165 ng/ml.
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.

Price/Size :

USD 368/1mg/vial



Tips: 

For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).

Describe :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.

Formula:

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.

Storage:

The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C. 


Note :

This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.
COPYRIGHT © 2015-2018 Bioworld Technology, Inc. All rights reserved POLYCLONAL AND MONOCLONAL ANTIBODY CENTER